Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 260 entries
Sorted by: Best Match Show Resources per page
Editorial overview.

Current opinion in immunology

Benoist C, Howard M.
PMID: 11102769
Curr Opin Immunol. 2000 Dec;12(6):661-3. doi: 10.1016/s0952-7915(00)00159-x.

No abstract available.

Cite
Benoist C, Howard M. Editorial overview. Curr Opin Immunol. 2000;12(6):661-3doi: 10.1016/s0952-7915(00)00159-x.
Benoist, C., & Howard, M. (2000). Editorial overview. Current opinion in immunology, 12(6), 661-3. https://doi.org/10.1016/s0952-7915(00)00159-x
Benoist, and Howard. "Editorial overview." Current opinion in immunology vol. 12,6 (2000): 661-3. doi: https://doi.org/10.1016/s0952-7915(00)00159-x
Benoist C, Howard M. Editorial overview. Curr Opin Immunol. 2000 Dec;12(6):661-3. doi: 10.1016/s0952-7915(00)00159-x. PMID: 11102769.
Copy Download .nbib Format: NLM
New insights into B cells as antigen presenting cells.

Current opinion in immunology

Ghosh D, Jiang W, Mukhopadhyay D, Mellins ED.
PMID: 34242927
Curr Opin Immunol. 2021 Jun;70:129-137. doi: 10.1016/j.coi.2021.06.003. Epub 2021 Jul 06.

In addition to their role as antibody producing cells, B cells make a critical contribution to adaptive immune responses by functioning as professional antigen-presenting cells (APC). Distinctive features of B cells as APC include the expression of the B...

Cite
Ghosh D, Jiang W, Mukhopadhyay D, et al. New insights into B cells as antigen presenting cells. Curr Opin Immunol. 2021;70:129-137doi: 10.1016/j.coi.2021.06.003.
Ghosh, D., Jiang, W., Mukhopadhyay, D., & Mellins, E. D. (2021). New insights into B cells as antigen presenting cells. Current opinion in immunology, 70129-137. https://doi.org/10.1016/j.coi.2021.06.003
Ghosh, Debopam, et al. "New insights into B cells as antigen presenting cells." Current opinion in immunology vol. 70 (2021): 129-137. doi: https://doi.org/10.1016/j.coi.2021.06.003
Ghosh D, Jiang W, Mukhopadhyay D, Mellins ED. New insights into B cells as antigen presenting cells. Curr Opin Immunol. 2021 Jun;70:129-137. doi: 10.1016/j.coi.2021.06.003. Epub 2021 Jul 06. PMID: 34242927.
Copy Download .nbib Format: NLM
Editorial overview: Indoles: very busy (and not indolent) molecules at work in immune regulation.

Current opinion in immunology

Grohmann U.
PMID: 34391570
Curr Opin Immunol. 2021 Jun;70:v-vii. doi: 10.1016/j.coi.2021.07.009.

No abstract available.

Cite
Grohmann U. Editorial overview: Indoles: very busy (and not indolent) molecules at work in immune regulation. Curr Opin Immunol. 2021;70:v-viidoi: 10.1016/j.coi.2021.07.009.
Grohmann, U. (2021). Editorial overview: Indoles: very busy (and not indolent) molecules at work in immune regulation. Current opinion in immunology, 70v-vii. https://doi.org/10.1016/j.coi.2021.07.009
Grohmann, Ursula. "Editorial overview: Indoles: very busy (and not indolent) molecules at work in immune regulation." Current opinion in immunology vol. 70 (2021): v-vii. doi: https://doi.org/10.1016/j.coi.2021.07.009
Grohmann U. Editorial overview: Indoles: very busy (and not indolent) molecules at work in immune regulation. Curr Opin Immunol. 2021 Jun;70:v-vii. doi: 10.1016/j.coi.2021.07.009. PMID: 34391570.
Copy Download .nbib Format: NLM
Resistance mechanisms to checkpoint inhibitors.

Current opinion in immunology

Weiss SA, Sznol M.
PMID: 33676271
Curr Opin Immunol. 2021 Apr;69:47-55. doi: 10.1016/j.coi.2021.02.001. Epub 2021 Mar 03.

Although multiple immune checkpoint inhibitors (ICI) have been identified and tested in the clinic, antibodies blocking the PD-1/PD-L1 axis have produced the greatest impact on cancer treatment. Many potential mechanisms of treatment failure have been proposed from pre-clinical animal...

Cite
Weiss SA, Sznol M. Resistance mechanisms to checkpoint inhibitors. Curr Opin Immunol. 2021;69:47-55doi: 10.1016/j.coi.2021.02.001.
Weiss, S. A., & Sznol, M. (2021). Resistance mechanisms to checkpoint inhibitors. Current opinion in immunology, 6947-55. https://doi.org/10.1016/j.coi.2021.02.001
Weiss, Sarah A, and Sznol, Mario. "Resistance mechanisms to checkpoint inhibitors." Current opinion in immunology vol. 69 (2021): 47-55. doi: https://doi.org/10.1016/j.coi.2021.02.001
Weiss SA, Sznol M. Resistance mechanisms to checkpoint inhibitors. Curr Opin Immunol. 2021 Apr;69:47-55. doi: 10.1016/j.coi.2021.02.001. Epub 2021 Mar 03. PMID: 33676271.
Copy Download .nbib Format: NLM
Criteria to make animal studies more relevant to treating human cancer.

Current opinion in immunology

Wolf SP, Wen FT, Schreiber H.
PMID: 34619458
Curr Opin Immunol. 2021 Oct 04;74:25-31. doi: 10.1016/j.coi.2021.09.002. Epub 2021 Oct 04.

Certain aspects of experimental tumor models in mice most accurately reflect the biology and immunology of cancer in patients. A survey of experimental cancer immunotherapy papers published in 2020 shows most do not achieve cancer shrinkage although treatment is...

Cite
Wolf SP, Wen FT, Schreiber H. Criteria to make animal studies more relevant to treating human cancer. Curr Opin Immunol. 2021;74:25-31doi: 10.1016/j.coi.2021.09.002.
Wolf, S. P., Wen, F. T., & Schreiber, H. (2021). Criteria to make animal studies more relevant to treating human cancer. Current opinion in immunology, 7425-31. https://doi.org/10.1016/j.coi.2021.09.002
Wolf, Steven P, et al. "Criteria to make animal studies more relevant to treating human cancer." Current opinion in immunology vol. 74 (2021): 25-31. doi: https://doi.org/10.1016/j.coi.2021.09.002
Wolf SP, Wen FT, Schreiber H. Criteria to make animal studies more relevant to treating human cancer. Curr Opin Immunol. 2021 Oct 04;74:25-31. doi: 10.1016/j.coi.2021.09.002. Epub 2021 Oct 04. PMID: 34619458.
Copy Download .nbib Format: NLM
Technophilia.

Current opinion in immunology

Davis MM.
PMID: 8793987
Curr Opin Immunol. 1996 Apr 01;8(2):255-6. doi: 10.1016/s0952-7915(96)80064-1.

No abstract available.

Cite
Davis MM. Technophilia. Curr Opin Immunol. 1996;8(2):255-6doi: 10.1016/s0952-7915(96)80064-1.
Davis, M. M. (1996). Technophilia. Current opinion in immunology, 8(2), 255-6. https://doi.org/10.1016/s0952-7915(96)80064-1
Davis. "Technophilia." Current opinion in immunology vol. 8,2 (1996): 255-6. doi: https://doi.org/10.1016/s0952-7915(96)80064-1
Davis MM. Technophilia. Curr Opin Immunol. 1996 Apr 01;8(2):255-6. doi: 10.1016/s0952-7915(96)80064-1. PMID: 8793987.
Copy Download .nbib Format: NLM
Therapeutic induction of tolerogenic dendritic cells via aryl hydrocarbon receptor signaling.

Current opinion in immunology

Barroso A, Mahler JV, Fonseca-Castro PH, Quintana FJ.
PMID: 33607496
Curr Opin Immunol. 2021 Jun;70:33-39. doi: 10.1016/j.coi.2021.02.003. Epub 2021 Feb 16.

Dendritic cells (DCs) are potent antigen-presenting cells (APCs), which sample the exogenous and endogenous cues to control adaptive immunity, balancing effector and regulatory components of the immune response. Multiple subsets of DCs, such as plasmacytoid and conventional DCs, have...

Cite
Barroso A, Mahler JV, Fonseca-Castro PH, et al. Therapeutic induction of tolerogenic dendritic cells via aryl hydrocarbon receptor signaling. Curr Opin Immunol. 2021;70:33-39doi: 10.1016/j.coi.2021.02.003.
Barroso, A., Mahler, J. V., Fonseca-Castro, P. H., & Quintana, F. J. (2021). Therapeutic induction of tolerogenic dendritic cells via aryl hydrocarbon receptor signaling. Current opinion in immunology, 7033-39. https://doi.org/10.1016/j.coi.2021.02.003
Barroso, Andreia, et al. "Therapeutic induction of tolerogenic dendritic cells via aryl hydrocarbon receptor signaling." Current opinion in immunology vol. 70 (2021): 33-39. doi: https://doi.org/10.1016/j.coi.2021.02.003
Barroso A, Mahler JV, Fonseca-Castro PH, Quintana FJ. Therapeutic induction of tolerogenic dendritic cells via aryl hydrocarbon receptor signaling. Curr Opin Immunol. 2021 Jun;70:33-39. doi: 10.1016/j.coi.2021.02.003. Epub 2021 Feb 16. PMID: 33607496.
Copy Download .nbib Format: NLM
Adverse events induced by immune checkpoint inhibitors.

Current opinion in immunology

Perdigoto AL, Kluger H, Herold KC.
PMID: 33640598
Curr Opin Immunol. 2021 Apr;69:29-38. doi: 10.1016/j.coi.2021.02.002. Epub 2021 Feb 25.

Immune checkpoint inhibitors have revolutionized the treatments of cancers but are also associated with immune related adverse events that can interfere with their use. The types and severity of adverse events vary with checkpoint inhibitors. A single mechanism of...

Cite
Perdigoto AL, Kluger H, Herold KC. Adverse events induced by immune checkpoint inhibitors. Curr Opin Immunol. 2021;69:29-38doi: 10.1016/j.coi.2021.02.002.
Perdigoto, A. L., Kluger, H., & Herold, K. C. (2021). Adverse events induced by immune checkpoint inhibitors. Current opinion in immunology, 6929-38. https://doi.org/10.1016/j.coi.2021.02.002
Perdigoto, Ana Luisa, et al. "Adverse events induced by immune checkpoint inhibitors." Current opinion in immunology vol. 69 (2021): 29-38. doi: https://doi.org/10.1016/j.coi.2021.02.002
Perdigoto AL, Kluger H, Herold KC. Adverse events induced by immune checkpoint inhibitors. Curr Opin Immunol. 2021 Apr;69:29-38. doi: 10.1016/j.coi.2021.02.002. Epub 2021 Feb 25. PMID: 33640598; PMCID: PMC8122053.
Copy Download .nbib Format: NLM
Interventions for vaccine hesitancy.

Current opinion in immunology

Ryan J, Malinga T.
PMID: 34271335
Curr Opin Immunol. 2021 Aug;71:89-91. doi: 10.1016/j.coi.2021.05.003. Epub 2021 Jul 13.

Despite overwhelming evidence of the effectiveness and safety of vaccinations, a growing number of people are reluctant to receive recommended vaccinations or refuse them altogether. Vaccination currently prevents 2-3 million deaths a year and a further 1.5 million deaths...

Cite
Ryan J, Malinga T. Interventions for vaccine hesitancy. Curr Opin Immunol. 2021;71:89-91doi: 10.1016/j.coi.2021.05.003.
Ryan, J., & Malinga, T. (2021). Interventions for vaccine hesitancy. Current opinion in immunology, 7189-91. https://doi.org/10.1016/j.coi.2021.05.003
Ryan, Jill, and Malinga, Thobile. "Interventions for vaccine hesitancy." Current opinion in immunology vol. 71 (2021): 89-91. doi: https://doi.org/10.1016/j.coi.2021.05.003
Ryan J, Malinga T. Interventions for vaccine hesitancy. Curr Opin Immunol. 2021 Aug;71:89-91. doi: 10.1016/j.coi.2021.05.003. Epub 2021 Jul 13. PMID: 34271335.
Copy Download .nbib Format: NLM
Indole derivatives, microbiome and graft versus host disease.

Current opinion in immunology

Qayed M, Michonneau D, Socié G, Waller EK.
PMID: 33647539
Curr Opin Immunol. 2021 Jun;70:40-47. doi: 10.1016/j.coi.2021.02.006. Epub 2021 Feb 26.

Graft versus host disease is a life-threatening complication following allogeneic hematopoietic stem cell transplantation driven by donor T cells reacting against disparate host antigens. Immune homeostasis within the gut plays a major role in the graft versus host response....

Cite
Qayed M, Michonneau D, Socié G, et al. Indole derivatives, microbiome and graft versus host disease. Curr Opin Immunol. 2021;70:40-47doi: 10.1016/j.coi.2021.02.006.
Qayed, M., Michonneau, D., Socié, G., & Waller, E. K. (2021). Indole derivatives, microbiome and graft versus host disease. Current opinion in immunology, 7040-47. https://doi.org/10.1016/j.coi.2021.02.006
Qayed, Muna, et al. "Indole derivatives, microbiome and graft versus host disease." Current opinion in immunology vol. 70 (2021): 40-47. doi: https://doi.org/10.1016/j.coi.2021.02.006
Qayed M, Michonneau D, Socié G, Waller EK. Indole derivatives, microbiome and graft versus host disease. Curr Opin Immunol. 2021 Jun;70:40-47. doi: 10.1016/j.coi.2021.02.006. Epub 2021 Feb 26. PMID: 33647539; PMCID: PMC8466652.
Copy Download .nbib Format: NLM
Application of T cell receptor (TCR) repertoire analysis for the advancement of cancer immunotherapy.

Current opinion in immunology

Joshi K, Milighetti M, Chain BM.
PMID: 34454284
Curr Opin Immunol. 2021 Aug 25;74:1-8. doi: 10.1016/j.coi.2021.07.006. Epub 2021 Aug 25.

T cell receptor (TCR) sequencing has emerged as a powerful new technology in analysis of the host-tumour interaction. The advances in NextGen sequencing technologies, coupled with powerful novel bioinformatic tools, allow quantitative and reproducible characterisation of repertoires from tumour...

Cite
Joshi K, Milighetti M, Chain BM. Application of T cell receptor (TCR) repertoire analysis for the advancement of cancer immunotherapy. Curr Opin Immunol. 2021;74:1-8doi: 10.1016/j.coi.2021.07.006.
Joshi, K., Milighetti, M., & Chain, B. M. (2021). Application of T cell receptor (TCR) repertoire analysis for the advancement of cancer immunotherapy. Current opinion in immunology, 741-8. https://doi.org/10.1016/j.coi.2021.07.006
Joshi, Kroopa, et al. "Application of T cell receptor (TCR) repertoire analysis for the advancement of cancer immunotherapy." Current opinion in immunology vol. 74 (2021): 1-8. doi: https://doi.org/10.1016/j.coi.2021.07.006
Joshi K, Milighetti M, Chain BM. Application of T cell receptor (TCR) repertoire analysis for the advancement of cancer immunotherapy. Curr Opin Immunol. 2021 Aug 25;74:1-8. doi: 10.1016/j.coi.2021.07.006. Epub 2021 Aug 25. PMID: 34454284.
Copy Download .nbib Format: NLM
Criteria to make animal studies more relevant to treating human cancer.

Current opinion in immunology

Wolf SP, Wen FT, Schreiber H.
PMID: 34619458
Curr Opin Immunol. 2021 Oct 04;74:25-31. doi: 10.1016/j.coi.2021.09.002. Epub 2021 Oct 04.

Certain aspects of experimental tumor models in mice most accurately reflect the biology and immunology of cancer in patients. A survey of experimental cancer immunotherapy papers published in 2020 shows most do not achieve cancer shrinkage although treatment is...

Cite
Wolf SP, Wen FT, Schreiber H. Criteria to make animal studies more relevant to treating human cancer. Curr Opin Immunol. 2021;74:25-31doi: 10.1016/j.coi.2021.09.002.
Wolf, S. P., Wen, F. T., & Schreiber, H. (2021). Criteria to make animal studies more relevant to treating human cancer. Current opinion in immunology, 7425-31. https://doi.org/10.1016/j.coi.2021.09.002
Wolf, Steven P, et al. "Criteria to make animal studies more relevant to treating human cancer." Current opinion in immunology vol. 74 (2021): 25-31. doi: https://doi.org/10.1016/j.coi.2021.09.002
Wolf SP, Wen FT, Schreiber H. Criteria to make animal studies more relevant to treating human cancer. Curr Opin Immunol. 2021 Oct 04;74:25-31. doi: 10.1016/j.coi.2021.09.002. Epub 2021 Oct 04. PMID: 34619458.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 260 entries